ABR-238901

SKU: orb1691558

Description

ABR-238901 is an oral, active S100A8/A9 blocker that inhibits the binding of S100A8/A9 to RAGE and TLR4 receptors. It shows potential for myocardial infarction treatment and is applied in cardiovascular research, including in vitro assays and in vivo models of cardiac injury.

Research Area

Immunology & Inflammation, Neuroscience

Key Properties

• CAS Number: 1638200-22-2
• MW: 394.63
• Purity: 99.15% (May vary between batches)
• Formula: C₁₁H₉BrClN₃O₄S
• SMILES: COc1ncc(cc1Br)S(=O)(=O)Nc1cncc(Cl)c1O
• Target: TLR
• Solubility: H2O:0.1 mg/mL (0.25 mM);DMSO:30 mg/mL (76.02 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.07 mM)

Bioactivity

• In Vivo:
  ABR-238901, given at a dose of 30 mg/kg/day through gavage over a period of 3 weeks, demonstrates reduced angiogenesis and lowered levels of IL6 and IL10 in MDSCs . When ABR-238901 (30 mg/kg/day via gavage) is combined with Bortezomib (0.6 mg/kg via subcutaneous injection, twice a week), it leads to a decreased tumor burden compared to using either agent alone . In C57BL/6NRJ mice with myocardial ischemia resulting from permanent coronary artery ligation, ABR-238901 administered at a dose of 30 mg/kg via intraperitoneal injection for the initial 3 days, followed by continuous oral administration daily for 21 days, induces progressive deterioration of cardiac function and accelerates left ventricular remodeling. However, when ABR-238901 is administered during the first 3 days post-myocardial infarction, it limits inflammatory damage and promotes a reparative environment .
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ABR 238901, ABR238901, ABR-238901, TLR4, S100A8/A9

Compound Identifiers

PubChem CID

86280668